FGFR2 and infantile convulsions and choreoathetosis: The use of molecularly targeted therapy has been most apparent in the management of iCCA, in which FGFR2 alterations (chiefly FGFR2 fusions and rearrangements) and IDH1/2 mutations occur in ~11–45% and ~5–36% of cases, respectively [10,72].